Stay updated on Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial

Sign up to get notified when there's something new on the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    The study page now presents the record for the LIBRETTO-531 trial of selpercatinib versus cabozantinib or vandetanib in RET-mutant medullary thyroid cancer, along with its study details and supporting information.
    Difference
    100%
    Check dated 2026-11-12T12:12:09.000Z thumbnail image
  2. Check
    7 days ago
    No Change Detected
  3. Check
    14 days ago
    Change Detected
    Summary
    The footer revision changes from v3.7.2 to v3.8.0; the page continues to show a 403 error.
    Difference
    0.2%
    Check dated 2026-10-29T13:28:07.000Z thumbnail image
  4. Check
    21 days ago
    Change Detected
    Summary
    A site-wide NIH banner announces transition updates and says the agency is using “Super Intelligence” in place of “Artificial Intelligence.”
    Difference
    1%
    Check dated 2026-10-22T13:51:22.000Z thumbnail image
  5. Check
    28 days ago
    Change Detected
    Summary
    The site footer's displayed revision advances from v3.7.1 to v3.7.2 on the study record's 403 Forbidden page.
    Difference
    0.3%
    Check dated 2026-10-15T13:11:17.000Z thumbnail image
  6. Check
    35 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.0 to v3.7.1, while the page continues to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-08T13:27:41.000Z thumbnail image
  7. Check
    49 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error with a simple header and a Home link, indicating restricted access rather than active content. The previously visible study details have been removed, leaving an error state.
    Difference
    19%
    Check dated 2026-09-24T18:07:24.000Z thumbnail image

Stay in the know with updates to Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page.